AXL inhibitors(AXL receptor tyrosine kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), MerTK inhibitors(Tyrosine-protein kinase Mer inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]

Active Indication

Non-Small Cell Lung CancerHepatocellular CarcinomaEGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma+ [4]

Inactive Indication

Advanced Malignant Solid NeoplasmFLT3 positive Acute Myeloid LeukemiaIntestinal Neoplasms+ [3]

Originator Organization

Dongguan Dongyangguang Pharmaceutical R&D Co. Ltd.

Active Organization

Sunshine Lake Pharma Co., Ltd.

Dongguan Dongyangguang Pharmaceutical R&D Co. Ltd.

Inactive Organization

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC38H37FN4O8S

InChIKeyNAUYISNCVNUUDK-UHFFFAOYSA-N

CAS Registry1394820-77-9

Clinical Trials associated with Ningetinib Tosylate

NCT04992858 / Not yet recruitingPhase 2

A Phase II Study of the Ningetinib in Advanced NSCLC With MET Exon 14 Skipping Mutations

This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations

Start Date27 Nov 2022

Sponsor / Collaborator

Sunshine Lake Pharma Co., Ltd.

NCT04601610 / TerminatedPhase 1/2

An Open, Multi-center, Ib/II Clinical Trial of KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced hepatocellular carcinoma.

Start Date07 Jun 2021

Sponsor / Collaborator

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

[+1]

CTR20210013 / TerminatedPhase 1/2

对甲苯磺酸宁格替尼联合KN046治疗晚期肝细胞癌的多中心、开放性、Ib/II期临床试验

[Translation] A multicenter, open-label, phase Ib/II clinical trial of Ningetinib tosylate combined with KN046 in the treatment of advanced hepatocellular carcinoma

主要目的评估KN046联合不同剂量的宁格替尼治疗晚期肝细胞癌的安全性和耐受性，确定其最大耐受剂量和推荐联合用药在后续临床试验的给药方案；评估在推荐给药方案下，KN046联合宁格替尼治疗晚期肝细胞癌的疗效。次要目的评估KN046联合宁格替尼治疗晚期肝细胞癌的安全性；评估联合用药时KN046和宁格替尼的药代动力学特征；评估KN046的免疫原性。探索目的探索肿瘤组织中c-Met、Axl的基因扩增或蛋白表达与疗效之间的相关性；探索肿瘤组织中生物标记物与疗效的相关性；评估KN046联合宁格替尼对HBsAg的影响

[Translation]

Main purpose To evaluate the safety and tolerability of KN046 combined with different doses of Ningetinib in the treatment of advanced hepatocellular carcinoma, determine its maximum tolerated dose and the recommended dosing regimen for combined use in subsequent clinical trials; To evaluate the efficacy of KN046 combined with Ningetinib in the treatment of advanced hepatocellular carcinoma under the recommended dosing regimen. Secondary purpose To evaluate the safety of KN046 combined with Ningetinib in the treatment of advanced hepatocellular carcinoma; To evaluate the pharmacokinetic characteristics of KN046 and Ningetinib when used in combination; To evaluate the immunogenicity of KN046. Exploratory purpose To explore the correlation between gene amplification or protein expression of c-Met and Axl in tumor tissues and efficacy; To explore the correlation between biomarkers in tumor tissues and efficacy; To evaluate the effect of KN046 combined with Ningetinib on HBsAg

Start Date20 May 2021

Sponsor / Collaborator

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

100 Clinical Results associated with Ningetinib Tosylate

100 Translational Medicine associated with Ningetinib Tosylate

100 Patents (Medical) associated with Ningetinib Tosylate

Literatures (Medical) associated with Ningetinib Tosylate

01 Feb 2024·Lung cancer (Amsterdam, Netherlands)

Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis

Article

Author: Zhang, Yingjun ; Feng, Guosheng ; Kang, Ning ; Chang, Jianhua ; Xie, Bo ; Zhang, Li ; Ren, Jun ; Ma, Yuxiang ; Fang, Jian ; Zeng, Shan ; Zhang, Qi ; Zhao, Hongyun ; Zhuang, Yulei ; Jiang, Yingzhi ; Ma, Haiqing ; Liu, Lianke ; Xi, Ning ; Zhao, Shen

BACKGROUND:

MET and AXL dysregulations are implicated in acquired resistance to EGFR-TKIs in NSCLC. But consensus on the optimal definition for MET/AXL dysregulations in EGFR-mutant NSCLC is lacking. Here, we investigated the efficacy and tolerability of ningetinib (a MET/AXL inhibitor) plus gefitinib in EGFR-mutant NSCLC, and evaluated the clinical relevance of MET/AXL dysregulations by different definitions.

METHODS:

Patients in this phase 1b dose-escalation/dose-expansion trial received ningetinib 30 mg/40 mg/60 mg plus gefitinib 250 mg once daily. Primary endpoints were tolerability (dose-escalation) and objective response rate (dose-expansion). MET/AXL status were analyzed using FISH and IHC.

RESULTS:

Between March 2017 and January 2021, 108 patients were enrolled. The proportion of MET focal amplification, MET polysomy, MET overexpression, AXL amplification and AXL overexpression is 18.1 %, 5.6 %, 55.8 %, 8.1 % and 45.3 %, respectively. 6.8 % patients have concurrent MET amplification and AXL overexpression. ORR is 30.8 % for tumors with MET amplification, 0 % for MET polysomy, 24.1 % for MET overexpression, 20 % for AXL amplification and 27.6 % for AXL overexpression. For patients with concurrent MET amplification and AXL overexpression, ningetinib plus gefitinib provides an ORR of 80 %, DCR of 100 % and median PFS of 4.7 months. Tumors with higher MET copy number and AXL expression tend to have higher likelihood of response. Biomarker analyses show that MET focal amplification and overexpression are complementary in predicting clinical benefit from MET inhibition, while AXL dysregulations defined by an arbitrary level may dilute the efficacy of AXL blockade.

CONCLUSIONS:

This study demonstrates that combined blockade of MET, AXL and EGFR is a feasible strategy for a subset of EGFR-mutant NSCLC.

TRIAL REGISTRATION:

Chinadrugtrials.org.cn, CTR20160875.

01 Jul 2022·Blood reviewsQ2 · MEDICINE

Current state and next-generation CAR-T cells in multiple myeloma

Q2 · MEDICINE

Review

Author: Facon, Thierry ; Mitra, Suman ; Manier, Salomon ; Nudel, Morgane ; Prodhomme, Chloé ; Escure, Guillaume ; Ingegnere, Tiziano

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a potentially transformative new approach to treating hematological malignancies. Ide-cel, an autologous B cell maturation antigen (BCMA) targeting CAR-T cells, has recently been approved to treat multiple myeloma (MM). Here, we review the main clinical trials of CAR-T cells in MM with the most advanced autologous BCMA-directed ide-cel and cilta-cel, the human CARs orva-cel and CT053, the alternative manufacturing process with P-BCMA-101 and bb21217, the dual CAR GC012F and the allogenic BCMA-directed CAR-T cells ALLO-715. In light of those clinical data, we provide an overview of CAR-T cells' main potential resistance mechanisms, including antigen loss, antigen spreading, anti-CAR antibodies, CAR-T cell exhaustion, and the emergence of a non-permissive microenvironment. Finally, we describe the principal area of research to build the next generation of CAR-T cells, with armored-, gated- or commuting-CARs, CARs associated with knock out of specific genes, and CAR-T cells made from γδT cells or NK cells.

01 Apr 2021·British journal of clinical pharmacologyQ2 · MEDICINE

Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non‐small cell lung cancer patients

Q2 · MEDICINE

Article

Author: Xie, Cen ; Sun, Mingming ; Xi, Ning ; Guo, Zitao ; Li, Jing ; Xie, Ningjie ; Liu, Lu ; Wang, Qian ; Li, Ming ; Hou, Xiangyu ; Chen, Xiaoyan

Aims:

Ningetinib is a tyrosine kinase inhibitor for the treatment of non‐small cell lung cancer (NSCLC). The present study aims to investigate the drug interaction of ningetinib and gefitinib and the mechanism of high plasma exposure of N‐demethylated ningetinib (M1) in NSCLC patients.

Methods:

Patients with NSCLC were recruited. Metabolism and transport assays were performed using in vitro models. Deuterated M1 was used to study the effects of ningetinib and gefitinib on M1 efflux in Institute of Cancer Research (ICR) mice.

Results:

Upon co‐administration of ningetinib with gefitinib, the plasma exposure of M1 was reduced by 80%, whereas that of ningetinib was not affected. In vitro experiments indicated that CYP1A1 was primarily responsible for M1 formation. Gefitinib was demonstrated to be a strong inhibitor of CYP1A1 with Ki value of 0.095 μM. M1 was identified as a substrate of efflux transporters P‐gp and BCRP, while ningetinib and gefitinib were demonstrated to be their inhibitors, which was consistent with the results in mice. However, the inhibitory effect of gefitinib on efflux in vivo was negligible in the presence of ningetinib.

Conclusion:

The high plasma exposure of M1 in patients was attributed to the inhibition of M1 efflux by ningetinib and its low tissue affinity. When co‐administered, gefitinib inhibited the formation of M1, but due to the low metabolic yield of M1 in vivo, the pharmacokinetics of ningetinib was not influenced. Inhibition of CYP1A1 may increase the concentration of ningetinib in target tissues, and the long‐term safety and efficacy of ningetinib combined with gefitinib should be evaluated.

News (Medical) associated with Ningetinib Tosylate

01 Mar 2024

·www.prnewswire.com

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

SHANGHAI, March 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration ("NMPA") of China has approved the New Drug Application ("NDA") for zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product candidate against BCMA), for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent). Zevorcabtagene autoleucel is an autologous BCMA-targeted CAR T-cell product, generated by transducing T cells with a lentivirus encoding a CAR comprising a fully human BCMA-specific single chain variable fragment ("scFv"), the human CD8α hinge domain, CD8α transmembrane domain, 4-1 BB co-stimulatory domain and CD3ζ activation domain. The proprietary novel fully-human scFv has high binding affinity and stability. The approval of zevorcabtagene autoleucel is based on an open-label, single arm, multi-center Phase II clinical trial (LUMMICAR STUDY 1, NCT03975907) conducted in China. The trial results were released at the 2022 Annual Meeting of the American Society of Hematology ("ASH"), and zevorcabtagene autoleucel demonstrated encouraging efficacy and a favorable safety profile. Multiple myeloma is an incurable malignant plasma cell disorder that accounts for approximately 10% of all hematological cancers.[1] With China's ageing population coupled with an increase in life expectancy, the number of patients with multiple myeloma is expected to expand. Frost & Sullivan forecasts that the prevalence of multiple myeloma in China in 2023 is approximately 153,000 per annum, and the number of new cases would be 23,200 per annum. It is estimated that the prevalence of multiple myeloma in China is expected to grow to 266,300 by 2030.[2] Prof. Wenming Chen, the principal investigator of the LUMMICAR STUDY 1, Director of Hematology Department, Beijing Chao-Yang Hospital, Capital Medical University, said, "In the realm of traditional treatments, the prognosis for patients dealing with relapsed or refractory multiple myeloma remains notably grim, given the limitations of available therapeutic alternatives. These individuals confront substantial unmet clinical needs, necessitating an expeditious adoption of an effective, safe, and convenient treatment modalities. The approval of zevorcabtagene autoleucel not only expands the array of choices available to clinical practitioners but also brings new hope to patients." Prof. Chengcheng Fu, the principal investigator of the LUMMICAR STUDY 1, Director of Hematology Department, the First Affiliated Hospital of Soochow University, said, "Based on the published results of the LUMMICAR-1 study, zevorcabtagene autoleucel has demonstrated profound and enduring therapeutic efficacy in patients with relapsed or refractory multiple myeloma, exhibiting overall favorable tolerability. We are pleased to witness the regulatory approval and market launch of zevorcabtagene autoleucel. We look forward to its potential to benefit a larger number of individuals, aiding them in achieving high-quality, long-term survival." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "This year marks the tenth anniversary of CARsgen, and I am delighted to announce the NDA approval of zevorcabtagene autoleucel. This achievement stands as a significant milestone in the company's development and serves as a testament to the unwavering dedication of our team. I would like to express heartfelt gratitude to our team members, investigators, patients, and the broader community for their support and trust. We look forward to zevorcabtagene autoleucel bringing renewed hope to adult patients with relapsed or refractory multiple myeloma, thereby improving their survival. Guided by the vision of 'Making Cancer Curable,' we remain committed to exploring new technologies, expanding our product pipeline with global rights to address the major challenges of CAR T-cell therapies, and bringing innovative and differentiated cell therapies to cancer patients worldwide." About Zevorcabtagene Autoleucel Zevorcabtagene autoleucel is a fully human, autologous BCMA CAR T-cell product for the treatment of R/R MM. As informed by the NMPA on March 1, 2024, zevorcabtagene autoleucel was approved on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (at least one proteasome inhibitor and immunomodulator). CARsgen is conducting a separate Phase 1b/2 LUMMICAR STUDY 2 clinical trial in North America to evaluate the safety and efficacy of zevorcabtagene autoleucel in R/R MM. Zevorcabtagene autoleucel received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the U.S. FDA in 2019, as well as Priority Medicines (PRIME) and Orphan Medicinal Product designations from the European Medicines Agency (EMA) in 2019 and 2020, respectively. Zevorcabtagene autoleucel also received Breakthrough Therapy designation from the NMPA in 2020. In January 2023, CARsgen and Huadong Medicine announced a collaboration for the commercialization of zevorcabtagene autoleucel in mainland China. Huadong Medicine was granted the exclusive right to commercialize zevorcabtagene autoleucel in mainland China. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has established a comprehensive CAR T-cell research and development platform, encompassing target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. CARsgen's vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, . No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit Public Relations: [email protected] Investor Relations: [email protected] SOURCE CARsgen Therapeutics

Clinical ResultPhase 2Orphan DrugDrug ApprovalImmunotherapy

14 Dec 2023

·firstwordpharma.com

CARsgen’s CAR-T therapies hit by FDA hold

CARsgen Therapeutics disclosed that the FDA recently placed a clinical hold on three of its investigational CAR T-cell therapies due to issues over chemistry, manufacturing and controls processes. The company said that the agency’s move follows the inspection of a manufacturing site located in Durham, North Carolina.The therapies affected include CT053, an autologous BCMA CAR T-cell product candidate for the treatment of refractory and/or relapsed multiple myeloma. The therapy, also known as zevorcabtagene autoleucel, is under regulatory review in China and is in Phase II/III development in the US. It is partnered with Huadong Medicine in China.Other drugs hit by the FDA hold include CT041, an autologous CAR T-cell product candidate against the protein Claudin18.2, which is in Phase II development for gastric, pancreatic and gastroesophageal junction cancer. Also affected is CT071, a Phase I autologous CAR T-cell therapy candidate targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma or relapsed/ refractory primary plasma cell leukaemia.The company said it will “conduct a comprehensive review and improvement on the current good manufacturing practice” at the plant.

Cell TherapyPhase 2ImmunotherapyPhase 1

16 Jan 2023

·www.prnewswire.com

CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, and Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (Huadong Medicine; SZ: 000963), today announced a collaboration for the commercialization of CARsgen's BCMA CAR-T product CT053 in mainland China. CT053, zevorcabtagene autoleucel ("zevor-cel"), is CARsgen's lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM). CT053 NDA was submitted to NMPA in October 2022. With strong commercial capability and network, Huadong Medicine is granted the exclusive right to commercialize zevor-cel in mainland China. "Huadong's extensive commercialization experience in mainland China along with their strategic goal of being a leader in the oncology therapeutic area created the opportunity for a strong, strategic and mutually beneficial partnership between our two companies," said Dr. Zonghai Li, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, "Despite advancements in recent years, there are still significant unmet medical needs for the treatment of multiple myeloma. Zevor-cel, a differentiated BCMA CAR T cell therapy, has shown promising data in clinical programs and is now under NDA priority review by NMPA. We believe this collaboration with Huadong Medicine will enhance the successful commercialization of zevor-cel in mainland China." "CARsgen is a leading biotech company in the development of innovative cell therapies for cancer patients and has built integrated R&D and manufacturing capabilities," added Liang Lv, Chairman of Huadong Medicine. "We are excited to collaborate with CARsgen to commercialize CT053. Leveraging Huadong's strong commercial presence in hematology, Huadong is committed to bringing CT053, an innovative and highly effective new treatment, to more R/R MM patients in China, and improve their survival and quality of life." Under the terms of the agreement, CARsgen will receive an upfront payment of RMB200 million and is eligible to receive regulatory and commercial milestone payments up to RMB1,025 million. CARsgen will continue to be responsible for the development, regulatory approval, and manufacturing of CT053 in mainland China. About CT053 CT053, zevorcabtagene autoleucel ("zevor-cel"), is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of R/R MM. The New Drug Application (NDA) based on the phase I/II data from LUMMICAR STUDY 1 in China has been accepted by NMPA. CARsgen is conducting the phase 1b/2 LUMMICAR STUDY 2 in North America to evaluate the safety and efficacy of CT053 for R/R MM in that population. The Company also plans additional clinical trials for earlier line multiple myeloma treatment. CT053 received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the U.S. FDA in 2019, as well as the Priority Medicines (PRIME) and Orphan Medicinal Product designations from the European Medicines Agency (EMA) in 2019 and 2020, respectively. CT053 also received Breakthrough Therapy designation from the NMPA in 2020. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The Company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors and reducing treatment costs. The Company's vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable. About Huadong Medicine Huadong Medicine Co., Ltd. (SZ.000963) is a leading large-scale comprehensive pharmaceutical listed company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales, and marketing capabilities. Huadong Medicine's product portfolio and pipeline are specialized in oncology, immunology, nephrology, and diabetes. Huadong Medicine has 12,000 employees and highly extensive commercial coverage and marketing capabilities in China. 'Patient Centered, Science Driven' is Huadong Medicine's value. For additional information, please visit . Contact Us For more information, please visit SOURCE CARsgen Therapeutics

License out/inOrphan DrugCell TherapyImmunotherapyClinical Study

100 Deals associated with Ningetinib Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16256

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 2	-	Sunshine Lake Pharma Co., Ltd.	27 Nov 2022
Hepatocellular Carcinoma	Phase 2	-	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	01 Dec 2020
Metastatic Renal Cell Carcinoma	Phase 2	CN	Sunshine Lake Pharma Co., Ltd.	25 Jun 2018
Renal Cell Carcinoma	Phase 2	CN	Sunshine Lake Pharma Co., Ltd.	25 Jun 2018
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	Phase 2	CN	Sunshine Lake Pharma Co., Ltd.	01 Nov 2016
Kidney Neoplasms	Phase 1	CN	Dongguan Dongyangguang Pharmaceutical R&D Co. Ltd.	30 Jan 2022
Leukemia	Phase 1	CN	Dongguan Dongyangguang Pharmaceutical R&D Co. Ltd.	30 Jan 2022
FLT3 positive Acute Myeloid Leukemia	Phase 1	CN	Sunshine Lake Pharma Co., Ltd.	13 Nov 2017
Relapsing acute myeloid leukemia	Phase 1	CN	Sunshine Lake Pharma Co., Ltd.	13 Nov 2017
Intestinal Neoplasms	Phase 1	CN	Sunshine Lake Pharma Co., Ltd.	08 Apr 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03758287 (ASCO2020) Manual	Phase 1	Non-Small Cell Lung Cancer T790M Negative	86	Gefitinib+ningetinib	iikgyjuhfz(lnsixlkadf) = ktpivdbuib rcvkgirdmq (xkzbkgoito ) View more	Positive	29 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis